Analysis of temporal and spatial diversity of RAS gene mutations in metastatic colorectal cancer

Dynamics analysis study of RAS in colorectal cancer - Dynamics analysis study of RAS in colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000053017

Enrollment

200

Registered

2023-12-07

Start date

2023-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with mCRC who have undergone or are undergoing chemotherapy (including the use of molecularly targeted drugs and immune checkpoint inhibitors).

Exclusion criteria

Exclusion criteria: Colitic cancer

Design outcomes

Primary

Measure	Time frame
The incidence of NeoRAS wild-type	—

Secondary

Measure	Time frame
1. Percentage of RAS status mutations during chemotherapy. 2. Percentage of neo-RAS wild-type anti-EGFR antibodies used. 3. RAS mutation rates in tissue samples and liquid biopsy. 4. Overall survival, progression-free survival of neo RAS wild-type and RAS mutant	—

Countries

Japan

Contacts

Public ContactKenta Iguchi

Kanagawa Cancer Center Department of colorectal surgery

igc.ken.surg@gmail.com0455202222

Outcome results